Shows / PCR Perspectives
PCR Perspectives
Stay at the forefront of interventions for valvular heart disease, coronary, and structural interventions with expert insights and perspectives. These interviews explore the techniques, tools, and key topics shaping the ever-evolving field of interventional cardiology
Hosted on Acast. See acast.com/privacy for more information.
Episodes
- PCR Perspectives
Risk evaluation in asymptomatic patients: what is the current and future role of CT angiography?
Ronak Rajani speaks with Carlos Collet at #europcr 2026 about the role of coronary CT angiography in cardiovascular risk assessment among asymptomatic…
- PCR Perspectives
What are the latest developments in TAVI for aortic regurgitation?
In this #europcr 2026 conversation, Andreas Baumbach speaks with Raj Makkar about one of the most rapidly evolving areas in structural heart interventions…
- PCR Perspectives
Why are most unstable coronary lesions missed by angiography?
In this #europcr 2026 interview, Davide Capodanno and Peter Libby discuss the role of inflammation in atherosclerosis and why many high-risk coronary plaques…
- PCR Perspectives
Who should we consider for tricuspid intervention in 2026?
Julien Dreyfus and Fabien Praz review the current indications and management of severe tricuspid regurgitation, highlighting that treatment is now recommended…
- PCR Perspectives
Perspectives from a neurologist and a cardiologist on LAA closure vs DOAC for stroke prevention
In this discussion, Lorenz Räber and David Seiffge review the latest evidence on percutaneous left atrial appendage (LAA) closure for stroke prevention…
- PCR Perspectives
How to anticipate a complex left atrial appendage closure intervention?
In this episode, Xavier Freixa and Nina Wunderlich discuss how to better anticipate challenges in LAA closure. Moving beyond traditional morphology…
- PCR Perspectives
What is the latest in the management of coronary artery disease in TAVI candidates?
Ole De Backer and Daniel Blackman discuss the management of coronary artery disease in TAVI candidates at #europcr 2026, focusing on whether PCI should be…
- PCR Perspectives
Reducing radiation exposure in the cath lab: What you need to know
In this discussion, Angeliki Kolyda and Shareefah Shereef highlight the importance of reducing radiation exposure in the cath lab for both patients and staff…
- PCR Perspectives
What is the role of AI in the cath lab of tomorrow?
Louis‑Marie Desroche and Joost Daemen explore the growing role of artificial intelligence in interventional cardiology. From risk stratification and CT-based…
- PCR Perspectives
Which patient should have renal denervation in 2026?
In this interview, Flavio Ribichini and Sofie Brouwers discuss the evolving role of renal denervation in the management of hypertension. Now endorsed by major…
- PCR Perspectives
How to identify and manage vulnerable plaque?
Hector Garcia joins Salvatore Brugaletta in a discussion on the concept of vulnerable plaque, a key topic in contemporary cardiology. Together, they review the…
- PCR Perspectives
What is new in intracoronary physiology in 2026 and why does it matter?
Javier Escaned and Niels Van Royen explore the evolving role of physiology in coronary assessment, with a focus on angiography-derived and imaging-derived…
- PCR Perspectives
An interview with Andreas Grüntzig Ethica Award winner EuroPCR 2026 - Roxana Mehran
Nina Van Der Hoeven meets Roxana Mehran, winner of the Andreas Grüntzig Ethica Award 2026, the highest distinction in interventional cardiology. At this stage…
- PCR Perspectives
Long-term mortality following PCI with DES vs. CABG for left main disease
Major LBT from EuroPCR 2026 This major late-breaking trial from #EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting…
- PCR Perspectives
Coronary revascularisation in TAVI: meta-analysis of 4 Trials
Major LBTs from EuroPCR 2026 How should coronary artery disease (CAD) be managed in patients undergoing TAVI? At #europcr 2026, Martin Leon and Roberto…
- PCR Perspectives
LAA closure vs. NOAC in patients with atrial fibrillation across age groups in the CHAMPION AF study
This major late-breaking trial from #EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left…
- PCR Perspectives
What does ORBITA CTO tell us about CTO PCI?
Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI. In this…
- PCR Perspectives
The art of prompting, how to ask AI the right questions?
In this podcast episode, Frédéric Bouisset and Louis-Marie Desroche explore why mastering AI prompting is becoming a key clinical skill for interventional…
- PCR Perspectives
Why is TAVI a different procedure in patient with pure aortic regurgitation?
In this podcast episode, Juan Granada, Michael Borger and Joao Cavalcante highlight that aortic insufficiency differs from aortic stenosis and is often…
- PCR Perspectives
How to manage current challenges of small aortic annulus?
Joanna Wykrzykowska and Hélène Eltchaninoff discuss challenges in treating patients with small aortic annuli, which are common, especially in women, and…
- PCR Perspectives
In what situation is emergency transcatheter valve intervention a valid alternative to surgery?
Azeem Latib and Giuseppe Tarantini discuss how transcatheter therapies are increasingly used to treat critically ill patients with severe valvular disease and…
- PCR Perspectives
What are the key considerations for transcatheter mitral paravalvular leak management?
Nina Wunderlich and Patrick Calvert discuss mitral paravalvular leaks, which are relatively common. Percutaneous closure is now the default approach, and…
- PCR Perspectives
What are the key considerations when managing combined mitral and tricuspid regurgitation?
Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and…
- PCR Perspectives
How are the 2025 ESC EACTS valvular guidelines going to impact my TAVI programme?
Bernard Prendergast and Fabien Praz discuss updates from the new ESC/EACTS guidelines on aortic stenosis. Key changes include expanding TAVI to patients aged…
- PCR Perspectives
Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild…
- PCR Perspectives
Is iatrogenic atrial septum defect closure a necessary procedure?
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects…
- PCR Perspectives
How to manage patients with aortic stenosis and coronary artery disease?
Tiffany Patterson and Davide Capodanno address the increasingly common scenario of managing coronary artery disease (CAD) in patients undergoing TAVI. With up…
- PCR Perspectives
How are the 2025 ESC/EACTS valvular guidelines going to impact my mitral programme?
Francesco Maisano interviews Michael Borger, co-chair of the 2025 ESC/EACS valvular heart disease guidelines, on their practical impact. The updated guidelines…
- PCR Perspectives
What are the key steps in pre procedural assessment for successful LAA closure?
Lorenz Räber and Kasper Korsholm highlight why pre-procedural imaging—particularly cardiac CT—has become essential for successful left atrial appendage…
- PCR Perspectives
The D-PACE scoring system - Can we predict high-grade conduction disturbances after TAVI?
Michael Joner and Francesco Saia discuss the newly developed D-PACE Score, a tool designed to predict delayed AV block occurring more than 24 hours after…
- PCR Perspectives
How do we meet the needs of women with heart valve disease?
In this #pcrlv2025 conversation, Ellen Ross and Marta Sitges discuss the recent initiative from Global Heart Hub, a patient association: an in-depth look at…
- PCR Perspectives
What are the key learnings from the 7-year follow-up of PARTNER 3?
Listen to this PCR London Valves 2025 interview with Philippe Généreux and Philippe Pibarot, who explore the 7-year results of PARTNER 3 in low-risk patients…
- PCR Perspectives
How are the new 2025 ESC/EACTS valvular guidelines going to impact my tricuspid programme?
While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical…
- PCR Perspectives
How to manage the challenges of TAVI in bicuspid disease?
What makes TAVI in bicuspid aortic valve disease so challenging—and how can those challenges be overcome? In this #europcr 2025 expert discussion, Chiara De…
- PCR Perspectives
What are the essentials of the provisional strategy for non-left main true bifurcation lesions?
Listen to this #europcr 2025 interview to see Giuseppe Di Gioia and Jens Flensted Lassen as they break down the essentials of the provisional strategy for…
- PCR Perspectives
EuroPCR 2025 Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
Howard Herrmann and Raj Makkar discuss valve under-expansion in the ACURATE neo2 from the IDE trial sub-study. Fluoroscopy showed about 22 % of valves were…
- PCR Perspectives
What is the latest in DCB practice?
Robert Byrne and Bruno Scheller discuss drug-coated balloon (DCB) angioplasty at #europcr 2025. Nearly 20 years after its introduction, where does DCB…
- PCR Perspectives
Redo TAVI: how to treat different TAVI platforms when they fail?
In this #europcr 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma explore the crucial aspects of repeat transcatheter valve replacement. They…
- PCR Perspectives
What are the emerging indications for TAVI in 2025?
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux reveal the hottest emerging TAVI indications for 2025 in this #europcr 2025 discussion. They…
- PCR Perspectives
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
When should TAVI be performed—and how should coronary disease be managed in these patients? Liesbeth Rosseel, Davide Capodanno, and Michael Joner explore two…
- PCR Perspectives
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
Simon Redwood interviews John Forrest, principal investigator of the Evolut Low Risk Bicuspid Study, during #europcr 2025. As TAVR moves into younger…
- PCR Perspectives
How to manage treatment dilemmas in STEMI patients with multivessel disease?
What’s the best approach for STEMI patients with multivessel disease? Angela Mcinerney, Natalia Pinilla, and Matthias Götberg share their perspectives on how…
- PCR Perspectives
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
In this #europcr 2025 interview, Davide Capodanno and Woong Chol Kang explore the latest insights from the 4D-ACS trial and what it could mean for…
- PCR Perspectives
What are the fundamentals of an upfront two-stent strategy for bifurcation PCI?
In this #europcr 2025 video, Nicola Ryan speaks with Dejan Milasinovic about when and how to adopt an upfront two-stent strategy in bifurcation PCI. The key is…
- PCR Perspectives
How to tailor transcatheter mitral therapies in 2025? A new era
In this #europcr 2025 discussion, Mayra Guerrero, Thomas Modine, and Philipp Lurz share their views on the evolving landscape of mitral valve treatment. While…
- PCR Perspectives
How to successfully approach calcified bifurcation lesions?
Calcified bifurcation lesions remain one of the toughest challenges in interventional cardiology, combining two high-risk features into one complex scenario…
- PCR Perspectives
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
How effective is cerebral protection during TAVI? Bernard Prendergast and Rajesh Kharbanda take a deep dive into this key procedural question, reviewing the…
- PCR Perspectives
How to implement the diagnosis of INOCA in everyday practice?
In this exchange, Vijay Kunadian and Javier Escaned explore the real-world implementation of INOCA (Ischemia with Non-Obstructive Coronary Arteries) and ANOCA…
- PCR Perspectives
How to manage coronary artery disease in TAVI candidates?
At #EuroPCR2025, Martine Gilard, Antonio Mangieri, and Marco Barbanti share their perspectives on managing coronary artery disease in patients scheduled for…
- PCR Perspectives
How to efficiently and safely manage calcified left main disease
Nicola Ryan and Flavio Ribichini discuss the challenges of treating the calcified left main stem. They break down the complexities of this high-risk condition…
- PCR Perspectives
Vulnerable plaque PCI after PREVENT
What does the PREVENT trial tell us about managing vulnerable plaques? Recorded during #europcr 2025, this discussion features Michael Haude and Thomas Cuisset…
- PCR Perspectives
FAITAVI - Major Late-Breaking Trial from EuroPCR 2025
Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session. As coronary artery disease is…
- PCR Perspectives
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
Cleverson Zukowski and Pablo Lamelas take a moment during #europcr 2025 to shed light on a major regional milestone: the first-ever guidelines for the…
- PCR Perspectives
What are the essential aspects of transcatheter LAA closure?
In this #europcr 2025 exchange, Ole De Backer and Philippe Garot explore the evolving landscape of transcatheter left atrial appendage (LAA) occlusion. From…
- PCR Perspectives
How to successfully approach CTO interventions: a step-by-step approach
Elliot Smith, Thomas Hovasse, and Roberto Garbo present a structured, step-by-step approach to chronic total occlusion (CTO) interventions, starting from…
- PCR Perspectives
What is the optimal TAVI access approach in contemporary practice?
What is the optimal TAVI access approach in today’s practice? In this conversation at PCR London Valves 2024, Ole De Backer and Maarten Vanhaverbeke break down…
- PCR Perspectives
What do we know about bleeding risk & antithrombotic management after tricuspid valve interventions?
How do we navigate the thin line between bleeding risk and thrombosis in high-risk patients undergoing tricuspid valve interventions? Marianna Adamo and Fabien…
- PCR Perspectives
What are the key specific considerations for TAVI in women?
Curious about the specific considerations for TAVI in women? Martine Gilard and Dan Blackman highlight the challenges women face in the diagnosis and treatment…
- PCR Perspectives
SAVR or TAVR: what is best for female patients?
Wondering which is the better option for female patients—SAVR or TAVR? Don’t miss this exchange between Hendrik Treede and Hélène Eltchaninoff. They explore…
- PCR Perspectives
Predictors and clinical relevance of residual tricuspid regurgitation after transcatheter repair
Curious about the latest advancements in transcatheter tricuspid valve interventions? Don't miss this discussion between Philipp Lurz and Lukas Stolz at PCR…